Navigation Links
Morphotek(R), Inc. and Cancer Innovations, Inc. Announce Evaluation and Option Agreement for Therapeutic Monoclonal Antibodies
Date:7/15/2009

EXTON, Pa., July 15 /PRNewswire/ -- Morphotek((R)), Inc., a subsidiary of Eisai Corporation of North America, and Cancer Innovations, Inc. (CII), a privately held biotechnology company specializing in the development of oncology products, today announced that they have entered into an evaluation and option agreement in which Morphotek will evaluate monoclonal antibodies targeting certain tumor-associated proteins.

The agreement with CII provides Morphotek access to several of CII's monoclonal antibodies. Morphotek will evaluate one or more of the antibodies and have the right to exercise an option for a license during the evaluation period. Should Morphotek choose to exercise its option, the parties will enter negotiations for a license under which Morphotek would receive an exclusive worldwide license to develop the antibodies for potential therapeutic, diagnostic and prophylactic use, and would retain the responsibility for the commercialization of the antibodies.

"We are delighted that CII has decided to partner with Morphotek," said Nicholas C. Nicolaides, Ph.D., President and CEO of Morphotek. "We believe that these antibodies provide a novel approach to targeting tumor-associated proteins. Antibody targeting of tumor-associated proteins has demonstrated promising anti-angiogenic activity in preclinical studies. We are pleased to be able to access these antibodies for evaluation and possible development as we continue to grow our therapeutic antibody portfolio."

"CII has developed several monoclonal antibodies, peptides and small molecules with potential applications in the treatment of cancer and neo-vascular disorders," said Toni Gray, President and CEO of CII. "This agreement with Morphotek has the potential for the development of new drug candidates for cancer."

Morphotek will apply its antibody discovery technologies, including its pro
'/>"/>

SOURCE Eisai Corporation of North America
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Morphotek(R), Inc. Announces Initiation of MORAb-009 Phase II Study in First- Line Treatment of Mesothelioma
2. Human Genome Sciences and Morphotek(R), Inc. Announce Collaboration to Discover, Develop and Commercialize Antibodies for Oncology and Immunology
3. Morphotek(R), Inc and Lonza Group Ltd Enter Into Manufacturing Services Agreement
4. Morphotek(R), Inc. Announces a Research Collaboration Agreement with Synageva BioPharma Corporation to Develop Potential Treatments for Cancer and Infectious Disease
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. Johns Hopkins to add Elekta Synergy S(R) to Cancer Treatment Lineup
7. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
8. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
9. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
10. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Lyme Research Alliance (LRA), the nation’s ... universities, today announced the awarding of seven grants worth ... cure for Lyme and other tick-borne diseases. , ... its history—over 20 grant proposals—a 100 percent increase from ... receive so many solid applications from talented scientists this ...
(Date:9/30/2014)... September 30, 2014 Rainbow Scientific, ... research products, recently opened an online store to ... culture product lines developed and manufactured by Biological ... store include Biological Industries’ Nutristem® serum-free, xeno-free reagents ... embryonic stem cell (hESC) culture. , The ...
(Date:9/30/2014)... 2014 UFP Technologies, a producer ... has recently introduced a custom insulated shipping container ... The new insulated shipper solves the issue of ... UFP Technologies’ BioShell is a universal storage container ... handling and shipping. The insulated shipper keeps frozen ...
(Date:9/30/2014)... Canada (PRWEB) September 30, 2014 Back in ... on 500 square feet. per employee, which included space for ... back then.” says Jeff Howell, partner at Nidea Corporate ... firm in Toronto. “By the year 2000, however, 250 ... now seeing that number come down to 175 to 225 ...
Breaking Biology Technology:Lyme Research Alliance Awards Nearly $600,000 in New Grants 2Lyme Research Alliance Awards Nearly $600,000 in New Grants 3Lyme Research Alliance Awards Nearly $600,000 in New Grants 4Rainbow Scientific, Inc. opens online store for state-of-the-art stem cell culture and cytogenetic reagents 2UFP Technologies Introduces Insulated Shipping Container For Bulk Drug Transportation 2UFP Technologies Introduces Insulated Shipping Container For Bulk Drug Transportation 3ITRA Global Reports on How Companies Are Squeezing More Employees into Less Office Space 2ITRA Global Reports on How Companies Are Squeezing More Employees into Less Office Space 3
... Alba Therapeutics Corporation today,announced that its Investigational ... of endogenous insulin production capacity in new-onset,type 1 ... deliberation period,by the U.S. Food and Drug Administration ... study in 2008 while focusing the majority,of its ...
... will review common U.S. laws on research and process labs ... offer practical ... in association with Lab Manager Magazine, will present a Web,conference ... EST. The online conference will review common U.S. federal laws,pertaining ...
... SAN CARLOS, Calif., Sept. 5 NeurogesX, Inc.,(Nasdaq: ... developing novel,pain management therapies, announced today the appointment ... directors. Since May 2006, Mr. Peacock,has been a ... Prior to joining SV Life Sciences, Mr. Peacock ...
Cached Biology Technology:Alba Therapeutics Announces IND for Beta Cell Preservation in Type 1 Diabetes Using AT-1001 2Sigma-Aldrich and Lab Manager Magazine Present Webinar On Laboratory Environmental, Health and Safety Compliance Strategies 2Sigma-Aldrich and Lab Manager Magazine Present Webinar On Laboratory Environmental, Health and Safety Compliance Strategies 3NeurogesX Appoints New Director to the Board 2NeurogesX Appoints New Director to the Board 3
(Date:9/29/2014)... Energy Joint Genome Institute (DOE JGI), a DOE ... 32 new projects have been selected for the ... lakes to Caribbean waters, and from plant root ... in forested watersheds, the CSP 2015 projects portfolio ... be extracted. , "These projects catalyze JGI,s ...
(Date:9/29/2014)... anti-tumour activity in patients with advanced BRAF V600E ... progressed after chemotherapy, according to phase II data ... Spain. , "Reports of lung cancers bearing ... these mutations may be associated with increased sensitivity ... Dr David Planchard, pulmonary oncologist at the Gustav-Roussy ...
(Date:9/29/2014)... is here, and that means beer. And ... cold one, taking that first sip and ... reacted to form compounds that cause an ... why beers get skunky, and what you ... going bad. Learn all about it at ...
Breaking Biology News(10 mins):2015 DOE JGI's science portfolio delves deeper into the Earth's data mine 22015 DOE JGI's science portfolio delves deeper into the Earth's data mine 32015 DOE JGI's science portfolio delves deeper into the Earth's data mine 42015 DOE JGI's science portfolio delves deeper into the Earth's data mine 52015 DOE JGI's science portfolio delves deeper into the Earth's data mine 62015 DOE JGI's science portfolio delves deeper into the Earth's data mine 72015 DOE JGI's science portfolio delves deeper into the Earth's data mine 82015 DOE JGI's science portfolio delves deeper into the Earth's data mine 9Promising results shown with targeted approaches in subsets of non-small cell lung cancer 2Promising results shown with targeted approaches in subsets of non-small cell lung cancer 3
... steps have public officials in your state or community taken ... who are obese has tripled in just 35 years. Local ... it either easy or hard for families to find fresh ... and be physically active. LOCAL GOVERNMENT ACTIONS TO PREVENT CHILDHOOD ...
... at Virginia Tech, Harvard and Drexel finish studying the locomotion ... has a few new ways to increase his own world-breaking ... to maneuver in tight places, or to hover in one ... has researchers wondering if they can create smarter materials that ...
... Zurich, Switzerland, August 18, 2009 / b3c newswire ... that, following the successful completion of key research ... disease has advanced into preclinical development, triggering milestone ... (NASDAQ: BIIB). Neurimmune partnered with Biogen Idec for ...
Cached Biology News:Tackling childhood obesity at the local level -- IOM report releases Sept. 1 2NSF Emerging Frontiers' program supports development of smart materials based on study of fish 2NSF Emerging Frontiers' program supports development of smart materials based on study of fish 3Neurimmune Therapeutics Announces Advancement of Alzheimers Program into Preclinical Development 2Neurimmune Therapeutics Announces Advancement of Alzheimers Program into Preclinical Development 3
Identify and characterize Phosphoinositide (PI(4,5)P2) binding...
... micro test tubes are used to store ... tubes have uniform walls for uniform heat ... O-ring screw caps. The O-rings are made ... operating range from -55 to 150 degrees ...
... Sac-Cel (Second Antibody Coated CELlulose) was ... Diagnostics of Dartford, Kent, one of the ... world. IDS acquired the product range in ... and clinical biochemists developing their own "in ...
Determine relative degree of protein binding to phosphoinositides...
Biology Products: